Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866603 · ClinicalTrials.gov registry record
Rostock International Parkinson's Disease Study (ROPAD)
A clinical trial of Parkinson's Disease, sponsored by CENTOGENE GmbH Rostock.
- Active
- Registry status
- 25,000
- Enrollment target
- 20
- Study locations
NCT03866603: Active study of Parkinson's Disease, sponsored by CENTOGENE GmbH Rostock.
NCT03866603 is a study of Parkinson's Disease that is active but no longer recruiting, run by CENTOGENE GmbH Rostock. The registered enrollment target is 25,000 participants, above the 477-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (5141% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03866603, a study of Parkinson's Disease, is active but no longer recruiting, sponsored by CENTOGENE GmbH Rostock.
- ACTIVE NOT RECRUITING
- Registry status
- 25,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.
Conditions Studied
Study Locations (20)
California
- Pharmacology Research Institute - Encino
- Neuro-Pain Medical Center - Fresno
- University of California (UC) San Diego - La Jolla
- Loma Linda University - Loma Linda
- Pharmacology Research Institute - Los Alamitos
- Pharmacology Research Institute - Newport Beach
Florida
- Parkinson's Disease and Movement Disorder Center of Baco Raton - Baco Raton
- Linfritz Research Institute - Coral Gables
- Renstar Medical Research - Ocala
- University of South Florida - Tampa
- Vero Beach Neurology & Research Institute - Vero Beach
Illinois
- Rush University Medical Center - Chicago
- Northshore University HealthSystem - Evanston
New York
- Dent Neurologic Institue - Amherst
- Stony Brook University School of Medicine - Brookhaven
Arizona
- Tucson Neuroscience Research - Tucson
Indiana
- Indiana University, Department of Neurology - Indianapolis
Michigan
- Michigan Institute for Neurological Disorders - Farmington Hills
Nevada
- WR-CRCN - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,000 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT03866603 still lists
NCT03866603 is an observational study that tracks outcomes without assigning an intervention. Its 25,000 participants enrollment target places it among the larger protocols in the corpus, above the 477-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (5141% higher).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03866603 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03866603 about?
NCT03866603 is a clinical study titled "Rostock International Parkinson's Disease Study (ROPAD)". Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.
What is the current status of trial NCT03866603?
This trial is currently active not recruiting. The enrollment target is 25,000 participants. The study started on 2019-05-30. Estimated completion is 2025-12-31.
What conditions does trial NCT03866603 study?
This clinical trial studies the following conditions: Parkinson's Disease.
Who is sponsoring clinical trial NCT03866603?
This trial is sponsored by CENTOGENE GmbH Rostock, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03866603 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03866603's enrollment target sits among peer trials
25,000 1st of 158 the highest of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT06589310 · 25,000 participants
Falcon Real World Evidence Registry
- NCT06773897 · 25,000 participants
Rutgers University Study of the Genetics of Breast Cancer.
- NCT06774417 · 25,000 participants · NA
Digital Strategies to Advance Help-Seeking - Aim 3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI